Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development (Q35818505)

10 August 2017

1 reference

title

Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development (English)

1 reference

10 August 2017

David A Cooper

1

1 reference

PubMed ID

15219553

10 August 2017

Joep M A Lange

series ordinal

2

1 reference

PubMed ID

15219553

10 August 2017

language of work or name

1 reference

1 July 2004

1 reference

Lancet Infectious Diseases

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

7

1 reference

10 August 2017

426-436

1 reference

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Oligopeptide inhibitors of HIV-induced syncytium formation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Identification of a major co-receptor for primary isolates of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Mode of insertion into a lipid membrane of the N-terminal HIV gp41 peptide segment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Furin is important but not essential for the proteolytic maturation of gp160 of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Morphogenesis and morphology of HIV. Structure-function relations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

The organization of the envelope projections on the surface of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

A general model for the transmembrane proteins of HIV and other retroviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Core structure of gp41 from the HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Atomic structure of the ectodomain from HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Atomic structure of a thermostable subdomain of HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

HIV entry and its inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Structural basis for membrane fusion by enveloped viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Protein design of an HIV-1 entry inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

LearnCoil-VMF: computational evidence for coiled-coil-like motifs in many viral membrane-fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Leash in the groove mechanism of membrane fusion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

The structural biology of type I viral membrane fusion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Influenza hemagglutinin is spring-loaded by a metastable native conformation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Capture of an early fusion-active conformation of HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Interstitial granulomatous drug reaction with a histological pattern of interstitial granulomatous dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Guillain‐Barre Syndrome Associated with Immune Reconstitution

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

HIV-associated bacterial pneumonia in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

The biology of interferon-alpha and the clinical significance of anti-interferon antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 Weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901058-8

7 January 2021

10.1016/S1473-3099(04)01058-8

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15219553